Taylor, EVP, operations & R&D, sells $10.6k in Sight Sciences (SGHT)

Sight Sciences reported Q4 2025 EPS of -$0.08 vs. -$0.15 expected and revenue of $20.4M vs. $20.17M consensus, a modest beat. The company was awarded $34M in a patent verdict against Alcon (including $5.5M lost profits and $28.5M in royalties), and William Blair reiterated an Outperform rating citing strong expense control. Insider Brenton Taylor sold 2,869 shares at a $3.70 average to cover RSU tax liability and continues to hold 267,807 shares. These developments support a positive near-term outlook for the stock and could move the individual equity by estimated low-single-digit percentage moves.

Analysis

The recent legal and operational developments materially shift bargaining leverage in the ophthalmic devices ecosystem: a small-cap IP holder now has credible pathways to monetize through royalties or exclusionary remedies, forcing large OEMs to reprice product economics, retool SKUs, or open settlement talks. That dynamic will compress margins for incumbents who must either absorb redesign costs or pay licensing fees, and it creates an opening for contract manufacturers and alternative-tech suppliers to capture urgent retrofit work over the next 6–18 months.

Near-term market moves are likely to be binary and headline-driven — expect large intraday swings around appeal filings, injunctive relief petitions, or settlement announcements. The substantive revenue impact, however, will be slow: licensing negotiations, revenue recognition, or lost-market-share recovery play out on 12–36 month horizons, so equity re-ratings should be evaluated on discounted future royalty streams rather than one-off awards.

Key tail risks: a successful appeals process or PTO validity challenges can erase the legal premium quickly; conversely, a fast settlement with recurring royalty rates in the mid-single digits of OEM sales would be a re-rating catalyst. Analysts reiterating coverage on expense control can understate top-line sensitivity — investors should separate operational execution from legal optionality when sizing positions.

From a competitive angle, second-order winners include niche suppliers able to supply redesign components and litigation funding vehicles that short-circuit the small-cap’s cash constraints. The consensus risk is binary thinking; either the market prices a permanent uplift or discounts everything as transitory — the truth will be incremental and measurable over multiple quarters.

Key Decisions for Investors

• Long SGHT (Sight Sciences) — build a 1–2% portfolio position in three tranches over 3 months; horizon 12–18 months. Risk: litigation reversal or failure to convert to recurring royalties; Reward: asymmetric if recurring royalties reach even ~5–8% of affected OEM sales (potential 2–3x upside). Use a hard stop at 35–40% drawdown.
• Pair trade: Long SGHT / Short ALC (Alcon) — equal notional over 6–12 months to capture royalty transfer and incumbent margin pressure. Hedge short leg with 6–9 month 10–15% OTM calls on ALC to cap losses. Target asymmetric payoff where ~25% adverse move on pair triggers re-evaluation.
• Options spec: Buy small, high-leverage SGHT call exposure — 9–12 month LEAPS or call spreads sized to 0.25–0.5% of capital to capture binary settlement upside. Downside = premium paid; target 3–5x return if settlement/royalty visibility emerges within 9–12 months.
• Short ALC protection trade — hold a tactical 0.5% short or buy 6–9 month puts if you expect extended litigation costs and margin pressure. Cap position with covered calls or buy-side collars; aim for 20–30% downside capture while limiting blow-up risk from an unexpected settlement favoring the OEM.